71 related articles for article (PubMed ID: 20869878)
21. Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C.
Isakov N; Galron D; Mustelin T; Pettit GR; Altman A
J Immunol; 1993 Feb; 150(4):1195-204. PubMed ID: 8432975
[TBL] [Abstract][Full Text] [Related]
22. IRX-2 increases the T cell-specific immune response to protein/peptide vaccines.
Naylor PH; Hernandez KE; Nixon AE; Brandwein HJ; Haas GP; Wang CY; Hadden JW
Vaccine; 2010 Oct; 28(43):7054-62. PubMed ID: 20708999
[TBL] [Abstract][Full Text] [Related]
23. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
Cornet S; Menez-Jamet J; Lemonnier F; Kosmatopoulos K; Miconnet I
Vaccine; 2006 Mar; 24(11):1880-8. PubMed ID: 16300869
[TBL] [Abstract][Full Text] [Related]
24. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells.
De Bruijn ML; Schuurhuis DH; Vierboom MP; Vermeulen H; de Cock KA; Ooms ME; Ressing ME; Toebes M; Franken KL; Drijfhout JW; Ottenhoff TH; Offringa R; Melief CJ
Cancer Res; 1998 Feb; 58(4):724-31. PubMed ID: 9485027
[TBL] [Abstract][Full Text] [Related]
25. Activation of human T lymphocytes by bryostatin.
Hess AD; Silanskis MK; Esa AH; Pettit GR; May WS
J Immunol; 1988 Nov; 141(10):3263-9. PubMed ID: 3263418
[TBL] [Abstract][Full Text] [Related]
26. Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition.
Samorski R; Gissmann L; Osen W
Immunol Lett; 2006 Sep; 107(1):41-9. PubMed ID: 16949679
[TBL] [Abstract][Full Text] [Related]
27. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
Cao X; Zhang W; He L; Xie Z; Ma S; Tao Q; Yu Y; Hamada H; Wang J
J Immunol; 1998 Dec; 161(11):6238-44. PubMed ID: 9834111
[TBL] [Abstract][Full Text] [Related]
28. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
[TBL] [Abstract][Full Text] [Related]
29. Potential involvement of monocyte chemoattractant protein (MCP)-1/CCL2 in IL-4-mediated tumor immunity through inducing dendritic cell migration into the draining lymph nodes.
Wang H; Nemoto-Sasaki Y; Kondo T; Akiyama M; Mukaida N
Int Immunopharmacol; 2003 May; 3(5):627-42. PubMed ID: 12757733
[TBL] [Abstract][Full Text] [Related]
30. Efficient induction of human T-cell leukemia virus-1-specific CTL by chimeric particle without adjuvant as a prophylactic for adult T-cell leukemia.
Kozako T; Fukada K; Hirata S; White Y; Harao M; Nishimura Y; Kino Y; Soeda S; Shimeno H; Lemonnier F; Sonoda S; Arima N
Mol Immunol; 2009 Dec; 47(2-3):606-13. PubMed ID: 19889459
[TBL] [Abstract][Full Text] [Related]
31. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
[TBL] [Abstract][Full Text] [Related]
32. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.
Flanagan K; Glover RT; Hörig H; Yang W; Kaufman HL
Vaccine; 2004 Jul; 22(21-22):2894-903. PubMed ID: 15246626
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxic T lymphocyte response induced by an improved synthetic lipopeptide vaccine against cervical cancer.
Xu DH; Zhou CH; Xia YP; Qiu ZY; Wu YZ; Jia ZC; Zhou W
Acta Pharmacol Sin; 2007 May; 28(5):695-702. PubMed ID: 17439726
[TBL] [Abstract][Full Text] [Related]
34. Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers.
Xu M; Lu X; Sposato M; Zinckgraf JW; Wu S; von Hofe E
Vaccine; 2009 Jul; 27(34):4641-7. PubMed ID: 19520206
[TBL] [Abstract][Full Text] [Related]
35. Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine.
Vasievich EA; Chen W; Huang L
Cancer Immunol Immunother; 2011 May; 60(5):629-38. PubMed ID: 21267720
[TBL] [Abstract][Full Text] [Related]
36. Challenges to the development of bryostatin-type anticancer drugs based on the activation mechanism of protein kinase Cδ.
Irie K; Yanagita RC; Nakagawa Y
Med Res Rev; 2012 May; 32(3):518-35. PubMed ID: 22539107
[TBL] [Abstract][Full Text] [Related]
37. The antineoplastic agent bryostatin-1 differentially regulates IFN-gamma receptor subunits in monocytic cells: transcriptional and posttranscriptional control of IFN-gamma R2.
Garcia CS; Curiel RE; Mwatibo JM; Pestka S; Li H; Espinoza-Delgado I
J Immunol; 2006 Aug; 177(4):2707-16. PubMed ID: 16888033
[TBL] [Abstract][Full Text] [Related]
38. Bryostatin-1 and IL-2 synergize to induce IFN-gamma expression in human peripheral blood T cells: implications for cancer immunotherapy.
Curiel RE; Garcia CS; Farooq L; Aguero MF; Espinoza-Delgado I
J Immunol; 2001 Nov; 167(9):4828-37. PubMed ID: 11673486
[TBL] [Abstract][Full Text] [Related]
39. IFN-gamma and T-bet expression in human dendritic cells from normal donors and cancer patients is controlled through mechanisms involving ERK-1/2-dependent and IL-12-independent pathways.
Li H; Wojciechowski W; Dell'Agnola C; Lopez NE; Espinoza-Delgado I
J Immunol; 2006 Sep; 177(6):3554-63. PubMed ID: 16951314
[TBL] [Abstract][Full Text] [Related]
40. The antineoplastic agent bryostatin-1 induces proinflammatory cytokine production in human monocytes: synergy with interleukin-2 and modulation of interleukin-2Rgamma chain expression.
Bosco MC; Rottschafer S; Taylor LS; Ortaldo JR; Longo DL; Espinoza-Delgado I
Blood; 1997 May; 89(9):3402-11. PubMed ID: 9129048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
